Vimian Group came into this Q3 2026 earnings release with momentum, the share price up roughly 21% over the past three months and closing at SEK40.90 on Friday. Expectations were high for another clean proof point on the animal health growth story. The headline was solid rather than spectacular. Revenue for the quarter landed at €120.3m and adjusted earnings before interest, tax, depreciation and amortisation reached €29.2m, implying a 24.3% margin. That profit profile did not trigger a dramatic rerating, which leaves you asking whether the recent rally already priced in this level of delivery.
Like the resilience in Vimian Group's revenue and EBITDA margin, but wondering if there are other animal health and healthcare stocks with the same pricing power plus even stronger balance sheets and cash generation? Benchmark this quarter's delivery against our list of solid balance sheet and fundamentals stocks (205 results) .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs Q3 2025):€120.3m vs. €104.3m (up about 15%)
-
Net Income, excl. extra items (Q3 2026 vs Q3 2025):€8.9m vs. €6.5m (higher year on year)
-
Basic EPS (Q3 2026 vs Q3 2025):€0.0167 vs. €0.0123 (higher earnings per share)
-
Adjusted EBITDA Margin (Q3 2026 vs Q3 2025):24.3% vs. 24.4% (largely unchanged profitability on this measure)
Earnings tell you how Q3 landed, but investors who care about what they are paying for Vimian Group often focus on the cash flowing through the business over time. When you line up those cash flows against the current share price, the stock could be a solid 20% undervalued .
Vimian bullish story: product and digital firepower
The upbeat view hinges on Vimian Group turning product depth and digital reach into faster growth and sturdier earnings.
"Expansion in high-margin, niche segments such as veterinary dental products and specialty pharmaceuticals, now supported by 75 product launches over 12 months, more than 60 products in the pipeline, and a new biologics focused R&D hub in France, points to continued mix shift toward higher value portfolios that can support revenue growth and adjusted EBITA margins."
Q3 shows this thesis working in practice. Double digit organic expansion in MedTech and Diagnostics, plus solid Specialty Pharma growth, lines up with that product push. Group adjusted EBITDA of €29.2m at a 24.3% margin indicates that the shift toward higher value areas has not diluted profitability.
Vimian bear case: cash, costs and tax still biting
The worry is that operational friction absorbs too much of Vimian Group's progress from products and services.
"The main factor that has to go right is that Vimian Group continues to execute on product launches, MedTech dental and orthopedics education efforts, and the international rollout of its Veterinary Services platform while managing working capital, central costs, and a higher effective tax rate."
Execution on launches and Vet Services looks solid, with 11% organic growth and 30.5% margin in that division and double digit MedTech expansion. Yet central costs rose to €3.0m, recurring incentive charges continue, net financial items stayed a drag, and the tax rate of about 31% remains elevated, so some of that operating progress still leaks out below EBITDA.
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for .
Hunt For Mispriced Cash Engines
Vimian Group just showed how a credible earnings story does not always settle every long term question. The real opportunity could sit in stocks that look undervalued before the crowd catches up.
-
Company 1 - 21% below our estimate - focuses on turning a concentrated housing land bank into new residential projects.
-
Company 2 - 30% below our estimate - supplies photonic tools as chipmakers restart capacity projects and biophotonics orders grow.
-
Company 3 - 45% below our estimate - sells large LED displays and control software as venues and transport networks adopt digital screens.
Those are three of them. See every one of the 201 undervalued companies on it →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VIMIAN.ST .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
